Evidence map›Paper›PMID 39687787›Full record

ArticleAmerican journal of preventive cardiology2024

Alirocumab and chest pain after acute coronary syndrome: An analysis of ODYSSEY OUTCOMES.

Gregory P Geba, Ruifeng Chen, Kasturi Talapatra, Taylor Brackin, Kusha A Mohammadi, Robert Pordy, Garen Manvelian, David J Maron, Gregory G Schwartz, Michael Szarek and 2 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of preventive cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01663402. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01663402 phase3completed

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

Ran2012Enrolled18,924Registered outcomes15Posted comparisons6ConditionsAtherosclerotic Cardiovascular DiseaseArmsAlirocumab, LMT, Placebo
Open the trial in the graph
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Gregory P GebaRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Ruifeng ChenRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Kasturi TalapatraRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Taylor BrackinRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Kusha A MohammadiRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Robert PordyRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Garen ManvelianRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
David J MaronStanford University School of Medicine, Stanford, California, USA.
Gregory G SchwartzUniversity of Colorado School of Medicine, Aurora, Colorado, USA.
Michael SzarekState University of New York, Downstate School of Public Health, Brooklyn, New York, USA.
Ph Gabriel StegUniversité Paris-Cité, Paris, France.
Sergio FazioRegeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients with recent acute coronary syndrome (ACS) commonly experience chest pain, which affects quality of life even when not due to recurrence of ACS. This post hoc analysis of ODYSSEY OUTCOMES assessed the effect of alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, on the incidence of chest pain not due to recurrent ACS. Methods: Patients with recent ACS ( Results: Chest pain not requiring hospitalization was reported as an adverse event in 1490 patients, including 7.5 % and 8.3 % of alirocumab and placebo groups, respectively. Hospitalization for chest pain negatively adjudicated for recurrent ACS occurred in 952 patients, including 4.8 % and 5.3 % of alirocumab and placebo groups, respectively. Adjusting for baseline covariates, alirocumab use was associated with 8.1 % lower risk of chest pain (either non-hospitalized or hospitalized events) versus placebo (HR: 0.919; 95 % CI: 0.845-0.998; Conclusions: Alirocumab use is associated with reduced incidence of chest pain events after ACS, including those not requiring hospitalization and those requiring hospitalization but not adjudicated as recurrent ACS. Trial registration: NCT01663402.

Indexed as

Acute coronary syndromeAlirocumabCardiovascular diseaseChest painLow-density lipoprotein cholesterolProprotein convertase subtilisin/kexin type 9

Identifiers

PMID39687787
PMCPMC11648769

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.